Pharmacoeconomics of liposomal anthracycline therapy

Charles L. Bennett, Elizabeth Calhoun

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Pharmacoeconomic analyses are being used with greater frequency in clinical oncology trials. These analyses provide guidelines for prioritizing competing interventions and allocating health care resources, particularly when deciding whether to use a drug with a higher acquisition cost. For liposomal anthracyclines, the competing treatments are other liposomal anthracyclines and nonliposomal chemotherapy agents with similar activity. Pharmacoeconomic analyses of data from clinical trials in patients with Kaposi's sarcoma determined that the overall cost to achieve objective response was substantially lower with pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]) than with liposomal daunorubicin (DaunoXome [DNX]). Additional economic analyses in patients with ovarian cancer showed that PLD has lower overall treatment costs than topotecan because it is administered less frequently and requires fewer interventions for toxicity. The decision to allocate health care resources to liposomal anthracycline treatment must therefore include consideration of cost-effectiveness and potential cost savings owing to improved tolerability.

Original languageEnglish (US)
Pages (from-to)191-195
Number of pages5
JournalSeminars in Oncology
Volume31
Issue numberSUPPL. 13
DOIs
StatePublished - Dec 2004
Externally publishedYes

Fingerprint

Pharmaceutical Economics
Anthracyclines
Health Resources
Therapeutics
Clinical Trials
Topotecan
Delivery of Health Care
Costs and Cost Analysis
Daunorubicin
Medical Oncology
Cost Savings
Kaposi's Sarcoma
Health Care Costs
Ovarian Neoplasms
Cost-Benefit Analysis
liposomal doxorubicin
Economics
Guidelines
Drug Therapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Pharmacoeconomics of liposomal anthracycline therapy. / Bennett, Charles L.; Calhoun, Elizabeth.

In: Seminars in Oncology, Vol. 31, No. SUPPL. 13, 12.2004, p. 191-195.

Research output: Contribution to journalArticle

Bennett, Charles L. ; Calhoun, Elizabeth. / Pharmacoeconomics of liposomal anthracycline therapy. In: Seminars in Oncology. 2004 ; Vol. 31, No. SUPPL. 13. pp. 191-195.
@article{30a3c473dd4c43a7b5cf8bf0124fbe7a,
title = "Pharmacoeconomics of liposomal anthracycline therapy",
abstract = "Pharmacoeconomic analyses are being used with greater frequency in clinical oncology trials. These analyses provide guidelines for prioritizing competing interventions and allocating health care resources, particularly when deciding whether to use a drug with a higher acquisition cost. For liposomal anthracyclines, the competing treatments are other liposomal anthracyclines and nonliposomal chemotherapy agents with similar activity. Pharmacoeconomic analyses of data from clinical trials in patients with Kaposi's sarcoma determined that the overall cost to achieve objective response was substantially lower with pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]) than with liposomal daunorubicin (DaunoXome [DNX]). Additional economic analyses in patients with ovarian cancer showed that PLD has lower overall treatment costs than topotecan because it is administered less frequently and requires fewer interventions for toxicity. The decision to allocate health care resources to liposomal anthracycline treatment must therefore include consideration of cost-effectiveness and potential cost savings owing to improved tolerability.",
author = "Bennett, {Charles L.} and Elizabeth Calhoun",
year = "2004",
month = "12",
doi = "10.1053/j.seminoncol.2004.08.008",
language = "English (US)",
volume = "31",
pages = "191--195",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 13",

}

TY - JOUR

T1 - Pharmacoeconomics of liposomal anthracycline therapy

AU - Bennett, Charles L.

AU - Calhoun, Elizabeth

PY - 2004/12

Y1 - 2004/12

N2 - Pharmacoeconomic analyses are being used with greater frequency in clinical oncology trials. These analyses provide guidelines for prioritizing competing interventions and allocating health care resources, particularly when deciding whether to use a drug with a higher acquisition cost. For liposomal anthracyclines, the competing treatments are other liposomal anthracyclines and nonliposomal chemotherapy agents with similar activity. Pharmacoeconomic analyses of data from clinical trials in patients with Kaposi's sarcoma determined that the overall cost to achieve objective response was substantially lower with pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]) than with liposomal daunorubicin (DaunoXome [DNX]). Additional economic analyses in patients with ovarian cancer showed that PLD has lower overall treatment costs than topotecan because it is administered less frequently and requires fewer interventions for toxicity. The decision to allocate health care resources to liposomal anthracycline treatment must therefore include consideration of cost-effectiveness and potential cost savings owing to improved tolerability.

AB - Pharmacoeconomic analyses are being used with greater frequency in clinical oncology trials. These analyses provide guidelines for prioritizing competing interventions and allocating health care resources, particularly when deciding whether to use a drug with a higher acquisition cost. For liposomal anthracyclines, the competing treatments are other liposomal anthracyclines and nonliposomal chemotherapy agents with similar activity. Pharmacoeconomic analyses of data from clinical trials in patients with Kaposi's sarcoma determined that the overall cost to achieve objective response was substantially lower with pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]) than with liposomal daunorubicin (DaunoXome [DNX]). Additional economic analyses in patients with ovarian cancer showed that PLD has lower overall treatment costs than topotecan because it is administered less frequently and requires fewer interventions for toxicity. The decision to allocate health care resources to liposomal anthracycline treatment must therefore include consideration of cost-effectiveness and potential cost savings owing to improved tolerability.

UR - http://www.scopus.com/inward/record.url?scp=11144265306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144265306&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2004.08.008

DO - 10.1053/j.seminoncol.2004.08.008

M3 - Article

C2 - 15717744

AN - SCOPUS:11144265306

VL - 31

SP - 191

EP - 195

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 13

ER -